Val
—
Gro
—
Qua
—
Mom
—
Sta
—
Cap—
P/SN/A
P/E—
Fwd P/E8.88
PEG2.91
52W— – —
RSI—
Target$28.75 (+14.3%)
Beta0.31
Div6.81%
Loading chart…
RSI (14)
Loading patterns…
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
52-Week Range
52W Low
—
52W High
Position in Range
—
RSI (14)
0 · Oversold
RSI 59
Overbought · 100
Signal
Neutral
EMA Price Levels
Volume Analysis
Momentum Dashboard
Trend Strength
Detected Patterns
0Bullish
3Bearish
0Neutral
▼ Double Top — Two peaks ~$27.37 — bearish reversal confirmed
▼ Bear Flag — Breakdown after -8% pole — bearish continuation
▼ Double Top — Two peaks ~$26.50 — bearish reversal confirmed
View overlays on the price chart via Chart tab → Pattern Overlays.
EPS — History & Forecast
Estimate
Beat
Miss
Forecast
Loading…
Revenue — History & Forecast
Revenue
Forecast
Loading…
EPS Beat Rate
100%
8/8 quarters
Wall Street Consensus
BUY
BuyHoldSell
Price Target Range
$28.75
+14.3% upside
Low $24
—
High $35
Consensus
Current price
Wall Street Analyst Ratings
| Firm | Rating | Change | Action | Date |
|---|---|---|---|---|
| BMO Capital | Outperform | — | ↔ Maintain | 2026-07-13 |
| Guggenheim | Buy | — | ↔ Maintain | 2026-07-13 |
| B of A Securities | Neutral | — | ↔ Maintain | 2026-07-10 |
| JP Morgan | Neutral | — | ↔ Maintain | 2026-07-08 |
| Cantor Fitzgerald | Neutral | — | ↔ Reiterate | 2026-07-06 |
| HSBC | Hold | Buy → Hold | ▼ Downgrade | 2026-07-06 |
| RBC Capital | Sector Perform | Underperform → Sector Perform | ▲ Upgrade | 2026-06-10 |
| Citigroup | Neutral | — | ↔ Maintain | 2026-04-29 |
| CICC | Outperform | — | ● Initiate | 2026-04-16 |
| UBS | Neutral | — | ↔ Maintain | 2026-04-13 |
| Morgan Stanley | Equal-Weight | — | ↔ Maintain | 2026-04-10 |
| Argus Research | Buy | Hold → Buy | ▲ Upgrade | 2026-03-02 |
| Barclays | Underweight | — | ● Initiate | 2026-02-20 |
| Freedom Broker | Buy | — | ↔ Maintain | 2026-02-09 |
BMO Capital
2026-07-13
Outperform
↔ Maintain
Guggenheim
2026-07-13
Buy
↔ Maintain
B of A Securities
2026-07-10
Neutral
↔ Maintain
JP Morgan
2026-07-08
Neutral
↔ Maintain
Cantor Fitzgerald
2026-07-06
Neutral
↔ Reiterate
HSBC
2026-07-06
Hold
(from Buy)
▼ Downgrade
RBC Capital
2026-06-10
Sector Perform
(from Underperform)
▲ Upgrade
Citigroup
2026-04-29
Neutral
↔ Maintain
CICC
2026-04-16
Outperform
● Initiate
UBS
2026-04-13
Neutral
↔ Maintain
Morgan Stanley
2026-04-10
Equal-Weight
↔ Maintain
Argus Research
2026-03-02
Buy
(from Hold)
▲ Upgrade
Barclays
2026-02-20
Underweight
● Initiate
Freedom Broker
2026-02-09
Buy
↔ Maintain
Profitability
Gross Margin
74.80%TTM
Op. Margin
31.62%TTM
ROE
8.31%TTM
Rev. Growth
5.40%YoY
Free Cash Flow
12.38BTTM
FCF Yield
—TTM
Balance Sheet
Debt / Equity
71.60MRQ
Current Ratio
1.25MRQ
Cash
13.08BMRQ
Total Debt
64.73BMRQ
Net Debt
—MRQ
Income
Div. Yield
6.81%TTM
Annual Rate
1.72Fwd
Payout Ratio
131.30%TTM
Dividend History
Payout Ratio (TTM): 131.30%
| Date | Amount / Share | Yield at Payment |
|---|---|---|
| 2026-07-24 | $0.4300 | 1.75% |
| 2026-05-08 | $0.4300 | 1.70% |
| 2026-01-23 | $0.4300 | 1.73% |
| 2025-11-07 | $0.4300 | 1.85% |
| 2025-07-25 | $0.4300 | 1.86% |
| 2025-05-09 | $0.4300 | 2.10% |
| 2025-01-24 | $0.4300 | 1.83% |
| 2024-11-08 | $0.4200 | 1.77% |
| 2024-07-26 | $0.4200 | 1.56% |
| 2024-05-09 | $0.4200 | 1.73% |
| 2024-01-25 | $0.4200 | 1.80% |
| 2023-11-09 | $0.4100 | 1.65% |
| 2023-07-27 | $0.4100 | 1.37% |
| 2023-05-11 | $0.4100 | 1.34% |
| 2023-01-26 | $0.4100 | 1.15% |
| 2022-11-03 | $0.4000 | 1.07% |
| 2022-07-28 | $0.4000 | 0.99% |
| 2022-05-12 | $0.4000 | 1.01% |
| 2022-01-27 | $0.4000 | 0.96% |
| 2021-11-04 | $0.3900 | 1.15% |
| 2021-07-29 | $0.3900 | 1.19% |
| 2021-05-06 | $0.3900 | 1.31% |
| 2021-01-28 | $0.3900 | 1.44% |
| 2020-11-05 | $0.3605 | 1.40% |
| 2020-07-30 | $0.3605 | 1.33% |
| 2020-05-07 | $0.3605 | 1.41% |
| 2020-01-30 | $0.3605 | 1.42% |
| 2019-11-07 | $0.3416 | 1.36% |
| 2019-08-01 | $0.3416 | 1.33% |
| 2019-05-09 | $0.3416 | 1.26% |
| 2019-01-31 | $0.3416 | 1.22% |
| 2018-11-08 | $0.3226 | 1.12% |
| 2018-08-02 | $0.3226 | 1.25% |
| 2018-05-10 | $0.3226 | 1.43% |
| 2018-02-01 | $0.3226 | 1.37% |
| 2017-11-09 | $0.3036 | 1.36% |
| 2017-08-02 | $0.3036 | 1.47% |
| 2017-05-10 | $0.3036 | 1.48% |
| 2017-02-01 | $0.3036 | 1.56% |
| 2016-11-08 | $0.2846 | 1.56% |
How PFE Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
| Quarter | Revenue | Rev YoY | Gross Profit | Op. Income | Net Income | Net YoY | Gross % | Op % | Net % |
|---|
Full Key Statistics
Valuation
| Market Cap | N/A |
| Enterprise Value | 195.29B |
| Trailing P/E | 19.20 |
| Forward P/E | 8.88 |
| PEG Ratio (5yr) | 2.91 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.59 |
| EV/Revenue | 3.08 |
| EV/EBITDA | 7.67 |
Share Statistics
| Avg Vol (3m) | 41.16M |
| Shares Outstanding | N/A |
| Float | 5.69B |
| % Held by Insiders | 0.10% |
| % Held by Institutions | 69.56% |
| Short Ratio | 3.21 |
| Short % of Float | 2.87% |
Profitability
| Gross Margin | 74.80% |
| Operating Margin (ttm) | 31.62% |
| Profit Margin | 11.83% |
| Return on Assets (ttm) | 5.69% |
| Return on Equity (ttm) | 8.31% |
Income Statement
| Revenue (ttm) | 63.32B |
| Revenue Growth (yoy) | 5.40% |
| Gross Profit (ttm) | 47.36B |
| EBITDA | 25.46B |
| Net Income (ttm) | 7.48B |
| Diluted EPS (ttm) | 1.31 |
| EPS Growth (yoy) | -10.10% |
Balance Sheet
| Total Cash (mrq) | 13.08B |
| Total Debt (mrq) | 64.73B |
| Debt / Equity (mrq) | 71.60 |
| Current Ratio (mrq) | 1.25 |
| Book Value / Share | 15.81 |
| Operating CF (ttm) | 11.98B |
| Free Cash Flow (ttm) | 12.38B |
Trading & Dividends
| Beta (5Y) | 0.31 |
| 50-Day MA | 25.11 |
| 200-Day MA | 25.83 |
| Fwd Dividend Yield | 681.00% |
| Payout Ratio | 131.30% |
Ownership Breakdown
Institutional 69.56%
Insider 0.10%
Public 30.3%
Short Interest
2.87% of float
Low
Institutional 13F Holdings
Famous investors who disclosed a position in PFE in their latest SEC 13F filing.
Loading…
Insider Transactions
| Date | Insider | Role | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-09 | DAMICO JENNIFER B. | Officer | Sale at price 25.70 per share. | 2,000 | $51,400 |
| 2026-03-03 | DAMICO JENNIFER B. | Officer | Stock Award(Grant) at price 0.00 per share. | 21,719 | — |
| 2026-02-25 | BOSHOFF CHRISTOFFEL | Officer | Stock Award(Grant) at price 0.00 per share. | 13,383 | — |
| 2026-02-25 | DAMICO JENNIFER B. | Officer | Conversion of Exercise of derivative security at price 33.82 per share. | 17,558 | $593,812 |
| 2026-02-25 | SAHNI PAYAL | Officer | Conversion of Exercise of derivative security at price 33.82 per share. | 56,888 | $1,923,952 |
| 2026-02-25 | MCDERMOTT MICHAEL | Officer | Conversion of Exercise of derivative security at price 33.82 per share. | 37,925 | $1,282,624 |
| 2026-02-25 | BOURLA ALBERT | Chief Executive Officer | Conversion of Exercise of derivative security at price 33.82 per share. | 491,626 | $16,626,791 |
| 2026-02-25 | LANKLER DOUGLAS M | Officer | Conversion of Exercise of derivative security at price 33.82 per share. | 122,907 | $4,156,715 |
| 2026-02-25 | FONSECA LIDIA PH.D. | Officer | Conversion of Exercise of derivative security at price 33.82 per share. | 56,888 | $1,923,952 |
| 2025-03-04 | DAMICO JENNIFER B. | Officer | Stock Award(Grant) at price 0.00 per share. | 5,583 | — |
| 2025-03-04 | DAMICO JENNIFER B. | Officer | Sale at price 25.93 per share. | 2,500 | $64,825 |
| 2025-02-27 | BOSHOFF CHRISTOFFEL | Officer | Stock Award(Grant) at price 0.00 per share. | 17,450 | — |
| 2025-02-27 | DAMICO JENNIFER B. | Officer | Conversion of Exercise of derivative security at price 31.31 per share. | 22,416 | $701,845 |
| 2025-02-27 | SAHNI PAYAL | Officer | Conversion of Exercise of derivative security at price 31.31 per share. | 19,054 | $596,581 |
| 2025-02-27 | MCDERMOTT MICHAEL | Officer | Conversion of Exercise of derivative security at price 31.31 per share. | 48,419 | $1,515,999 |
| 2025-02-27 | BOURLA ALBERT | Chief Executive Officer | Conversion of Exercise of derivative security at price 31.31 per share. | 582,823 | $18,248,188 |
| 2025-02-27 | LANKLER DOUGLAS M | Officer | Conversion of Exercise of derivative security at price 31.31 per share. | 156,914 | $4,912,977 |
| 2025-02-27 | FONSECA LIDIA PH.D. | Officer | Conversion of Exercise of derivative security at price 31.31 per share. | 72,629 | $2,274,014 |
| 2025-02-27 | SUSMAN SALLY | Officer | Conversion of Exercise of derivative security at price 31.31 per share. | 85,182 | $2,667,048 |
| 2025-02-26 | BOSHOFF CHRISTOFFEL | Officer | Stock Award(Grant) at price 0.00 per share. | 9,687 | — |
| 2025-02-21 | BOSHOFF CHRISTOFFEL | Officer | Conversion of Exercise of derivative security at price 30.17 per share. | 8,741 | $263,716 |
| 2025-02-21 | BOSHOFF CHRISTOFFEL | Officer | Conversion of Exercise of derivative security at price 30.17 per share. | 8,741 | $263,716 |
| 2025-02-21 | DAMICO JENNIFER B. | Officer | Conversion of Exercise of derivative security at price 30.17 per share. | 8,741 | $263,716 |
| 2025-02-21 | SAHNI PAYAL | Officer | Conversion of Exercise of derivative security at price 30.17 per share. | 12,714 | $383,581 |
| 2025-02-21 | MCDERMOTT MICHAEL | Officer | Conversion of Exercise of derivative security at price 30.17 per share. | 11,125 | $335,641 |
DAMICO JENNIFER B.
Officer
Sale at price 25.70 per share.
2026-06-09
2,000 sh
$51,400
DAMICO JENNIFER B.
Officer
Stock Award(Grant) at price 0.00 per share.
2026-03-03
21,719 sh
—
BOSHOFF CHRISTOFFEL
Officer
Stock Award(Grant) at price 0.00 per share.
2026-02-25
13,383 sh
—
DAMICO JENNIFER B.
Officer
Conversion of Exercise of derivative security at price 33.82 per share.
2026-02-25
17,558 sh
$593,812
SAHNI PAYAL
Officer
Conversion of Exercise of derivative security at price 33.82 per share.
2026-02-25
56,888 sh
$1,923,952
MCDERMOTT MICHAEL
Officer
Conversion of Exercise of derivative security at price 33.82 per share.
2026-02-25
37,925 sh
$1,282,624
BOURLA ALBERT
Chief Executive Officer
Conversion of Exercise of derivative security at price 33.82 per share.
2026-02-25
491,626 sh
$16,626,791
LANKLER DOUGLAS M
Officer
Conversion of Exercise of derivative security at price 33.82 per share.
2026-02-25
122,907 sh
$4,156,715
FONSECA LIDIA PH.D.
Officer
Conversion of Exercise of derivative security at price 33.82 per share.
2026-02-25
56,888 sh
$1,923,952
DAMICO JENNIFER B.
Officer
Stock Award(Grant) at price 0.00 per share.
2025-03-04
5,583 sh
—
DAMICO JENNIFER B.
Officer
Sale at price 25.93 per share.
2025-03-04
2,500 sh
$64,825
BOSHOFF CHRISTOFFEL
Officer
Stock Award(Grant) at price 0.00 per share.
2025-02-27
17,450 sh
—
DAMICO JENNIFER B.
Officer
Conversion of Exercise of derivative security at price 31.31 per share.
2025-02-27
22,416 sh
$701,845
SAHNI PAYAL
Officer
Conversion of Exercise of derivative security at price 31.31 per share.
2025-02-27
19,054 sh
$596,581
MCDERMOTT MICHAEL
Officer
Conversion of Exercise of derivative security at price 31.31 per share.
2025-02-27
48,419 sh
$1,515,999
BOURLA ALBERT
Chief Executive Officer
Conversion of Exercise of derivative security at price 31.31 per share.
2025-02-27
582,823 sh
$18,248,188
LANKLER DOUGLAS M
Officer
Conversion of Exercise of derivative security at price 31.31 per share.
2025-02-27
156,914 sh
$4,912,977
FONSECA LIDIA PH.D.
Officer
Conversion of Exercise of derivative security at price 31.31 per share.
2025-02-27
72,629 sh
$2,274,014
SUSMAN SALLY
Officer
Conversion of Exercise of derivative security at price 31.31 per share.
2025-02-27
85,182 sh
$2,667,048
BOSHOFF CHRISTOFFEL
Officer
Stock Award(Grant) at price 0.00 per share.
2025-02-26
9,687 sh
—
BOSHOFF CHRISTOFFEL
Officer
Conversion of Exercise of derivative security at price 30.17 per share.
2025-02-21
8,741 sh
$263,716
BOSHOFF CHRISTOFFEL
Officer
Conversion of Exercise of derivative security at price 30.17 per share.
2025-02-21
8,741 sh
$263,716
DAMICO JENNIFER B.
Officer
Conversion of Exercise of derivative security at price 30.17 per share.
2025-02-21
8,741 sh
$263,716
SAHNI PAYAL
Officer
Conversion of Exercise of derivative security at price 30.17 per share.
2025-02-21
12,714 sh
$383,581
MCDERMOTT MICHAEL
Officer
Conversion of Exercise of derivative security at price 30.17 per share.
2025-02-21
11,125 sh
$335,641